<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04103762</url>
  </required_header>
  <id_info>
    <org_study_id>PI2017_843_0020</org_study_id>
    <nct_id>NCT04103762</nct_id>
  </id_info>
  <brief_title>Interest of Intravenous Cholangiography With Indocyanine Green in the Context of Laparoscopic Cholecystectomy for Grade 1 and 2 Acute Gallstone Cholecystitis</brief_title>
  <acronym>VIFCAL</acronym>
  <official_title>Interest of Intravenous Cholangiography With Indocyanine Green, Compared to Contrast Cholangiography, in the Context of Laparoscopic Cholecystectomy for Grade 1 and 2 Acute Gallstone Cholecystitis: Prospective, Monocentric, Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire, Amiens</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute lithiasis cholecystitis (ALC) is the third most common cause of surgical emergency
      admission. The initial treatment of ALC associates a medical support and a cholecystectomy,
      preferentially performed laparoscopically in the first 5 days of evolution. During the
      surgery, intraoperative cholangiography (CPO) using a contrast product is the &quot;gold standard&quot;
      to identify the bile ducts. However CPO is performed in approximately 30% of laparoscopic
      cholecystectomy.

      Laparoscopic cholecystectomy for ALC is associated with an increase in the rate of biliary
      ducts injuries compared with cholecystectomy for symptomatic vesicular lithiasis, evaluated
      at 0.8 % versus 0.1 %. Its higher rate is related to local inflammation that alters the
      biliary anatomy and complicates the identification of the bile ducts. Indocyanine green
      facilitates the visualization of extrahepatic biliary structures, which could reduce the risk
      of biliary wound and shorten the operating time.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2019</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of surgical procedure after Indocyanine green injection</measure>
    <time_frame>day 0 = the day of the surgery</time_frame>
    <description>Change of surgical procedure after Indocyanine green injection compared to intraoperative cholangiography (CPO) using a contrast product as the &quot;gold standard&quot; to identify the bile ducts.
Indocyanine green facilitates the visualization of extrahepatic biliary structures, which could reduce the risk of biliary wound and shorten the operating time.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of CPO (intraoperative cholangiography) achievement rates with visualized rates of the main bile duct via indocyanine green</measure>
    <time_frame>day 0 = the day of the surgery</time_frame>
    <description>Comparison of CPO (intraoperative cholangiography) achievement rates with visualized rates of the main bile duct via indocyanine green</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of biliary element recognition rate during laparoscopic cholecystectomy between CPO (intraoperative cholangiography) group and Indocyanine green injection (ICG) group before dissection</measure>
    <time_frame>day 0 = the day of the surgery</time_frame>
    <description>Comparison of biliary element recognition rate during laparoscopic cholecystectomy between CPO (intraoperative cholangiography) group and Indocyanine green injection (ICG) group before dissection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of biliary element recognition rate during laparoscopic cholecystectomy between CPO (intraoperative cholangiography) group and Indocyanine green injection (ICG) group after dissection</measure>
    <time_frame>day 0 = the day of the surgery</time_frame>
    <description>Comparison of biliary element recognition rate during laparoscopic cholecystectomy between CPO (intraoperative cholangiography) group and Indocyanine green injection (ICG) group after dissection</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">128</enrollment>
  <condition>Lithiasis</condition>
  <condition>Cholecystitis, Acute</condition>
  <condition>Cholangiopathy</condition>
  <arm_group>
    <arm_group_label>indocyanine green</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During the surgery, intraoperative cholangiography using indocyanine green will be performed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard cpo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>During the surgery, intraoperative cholangiography using a contrast product &quot;gold standard&quot; will be performed</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>laparoscopic cholecystectomy</intervention_name>
    <description>laparoscopic cholecystectomy</description>
    <arm_group_label>indocyanine green</arm_group_label>
    <arm_group_label>standard cpo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>systematic intraoperative cholangiography</intervention_name>
    <description>systematic intraoperative cholangiography in both groups (use of Indocyanine Green in ICG group and Iomeron in the CPO group)</description>
    <arm_group_label>indocyanine green</arm_group_label>
    <arm_group_label>standard cpo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults patient (&gt;18 years old)

          -  Patients requiring laparoscopic cholecystectomy for grade 1 or 2 acute gallstone
             cholecystitis according to Tokyo recommendations confirmed by radiological
             morphological examination

          -  Acute lithiasis cholecystitis (ALC) evolving for less than 5 days

          -  Patients affiliated to a social security scheme

        Exclusion Criteria:

          -  Antecedent of biliary tract surgery

          -  Antecedent of cholecystectomy

          -  Contraindication to laparoscopy

          -  Contraindication to surgery

          -  Cholecystectomy by laparotomy out of hand

          -  Grade 3 cholecystitis according to Tokyo recommendations

          -  Acute alithiasis cholecystitis

          -  Cirrhosis

          -  Conversion for gangrenous ALC

          -  Patient with an allergy to indocyanine green

          -  Pregnant or lactating woman, childbearing age without effective contraception

          -  Minor patient

          -  Physical or psychological state that does not allow participation in the study,
             patient under guardianship or curatorship or patient deprived of liberty by a judicial
             or administrative decision (according with articles L 1121-6 and L 1121-8 of the
             French Public Health Code)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Osama ABOU ARAB, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Amiens</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Emilie Dumange Chapuis-Roux, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Amiens</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ralucar Macovei, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Amiens</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Baptiste Brac, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Amiens</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aur√©lien Gracient, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Amiens</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Marc Regimbeau, Pr</last_name>
    <phone>(33)322088893</phone>
    <email>regimbeau.jean.marc@chu-amiens.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80480</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Jean-Marc Regimbeau, Pr</last_name>
      <phone>(33)322088893</phone>
      <email>regimbeau.jean-marc@chu-amiens.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 19, 2019</study_first_submitted>
  <study_first_submitted_qc>September 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2019</study_first_posted>
  <last_update_submitted>October 3, 2019</last_update_submitted>
  <last_update_submitted_qc>October 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acute lithiasis cholecystitis</keyword>
  <keyword>intraoperative cholangiography</keyword>
  <keyword>indocyanine green</keyword>
  <keyword>cholecystectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholecystitis</mesh_term>
    <mesh_term>Acalculous Cholecystitis</mesh_term>
    <mesh_term>Gallstones</mesh_term>
    <mesh_term>Cholecystitis, Acute</mesh_term>
    <mesh_term>Lithiasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

